|
Jul 25
|
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
|
|
Jul 25
|
Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
|
|
Jul 16
|
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
|
|
Jul 15
|
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
|
|
Jun 27
|
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
|
|
Jun 20
|
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
|
|
Jun 12
|
Sobi share new clinical data across multiple hematologic diseases at EHA 2025
|
|
Apr 30
|
Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...
|
|
Apr 29
|
Sobi publishes Q1 2025 report: Portfolio continues to deliver
|
|
Oct 18
|
High Growth Tech Stocks In Sweden With Promising Potential
|
|
Aug 30
|
High Growth Tech Stocks In Sweden To Watch This August 2024
|
|
Aug 29
|
Sobi has completed issues of class C shares
|
|
Jun 19
|
European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
|
|
May 8
|
Sobi has completed SEK 3 billion senior bond issue
|
|
Apr 4
|
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
|
|
Apr 2
|
Sobi publishes Annual and sustainability report for 2023
|
|
Nov 30
|
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)
|
|
Nov 20
|
Sobi to present new data at ASH 2023 Annual Meeting
|